Dr. Kaufmann's appointment, with her vast experience in neur...

Dr. Kaufmann's appointment, with her vast experience in neurological and rare diseases, is anticipated to benefit Vigil as it progresses the development of its drugs iluzanebart and VG-3927. Her expertise in both domestic and global drug development is considered a valuable asset for the company.